Psychedelic scientist. Seminal psychedelic research for 22 yrs at Hopkins. Drugs, behavioral economics, addiction.
Baltimore, MD
Joined July 2017
- Tweets3.5K
- Following775
- Followers33.4K
- Likes44.3K
Pinned Tweet
It’s official. I just receive a U01 grant from NIDA to study #psilocybin for tobacco addiction. To my knowledge it's the 1st grant from the US government in over a half century to directly study therapeutics of a classic #psychedelic. New era in legitimacy of psychedelic science.
Conclusion to my comments in response to the FDA psychedelic hearing:
"These protections should preserve patients’ freedom to understand their experiences within their own religious, spiritual, agnostic, or atheistic frameworks. The purpose is not to suppress spirituality, but to prevent medical professionals from converting clinical authority into spiritual authority. Psychedelic treatments may have substantial therapeutic value, but their unusual capacity to produce profound meaning makes traditional professional boundaries more—not less—important."
Just saw a psychedelic conference post saying it was "the most important research in human history." The egos in psychedelic research are next level. I used to hear this stuff all the time at Hopkins, about this research saving the human species. I've been doing psychedelic research for 22 years and I don't even do the most important research in my own family!! (my wife does research informing how to save babies deprived of oxygen during childbirth).
And to be clear - I've also met many of the most kind and humble people in my life in the psychedelic field. My point is more that it's a mixed bag, just like the rest of humanity. You certainly get the extremes.
With all the momentum with psychedelics, this is the perhaps most important, ignored policy issue. Psychedelic medicine supporters will be astonished if/when MDMA & psilocybin are FDA approved but almost all of these substances remain schedule I. Spreading the word can help change that. @Ravarora1
illusionconsensus.com/p/psyc…
Matthew W. Johnson retweeted
Do you live in the San Francisco Bay Area? Are you planning a psychedelic experience? Willing to have an MRI before and a few weeks after? Maybe you're eligible for our study here: carhartharrislab.com/studies…
🤖 Made with AI
Matthew W. Johnson retweeted
An LSD published in 1973 found it helped heroin addiction. This was 3 years after it was a Schedule 1 drug.
@Drug_Researcher Dr. Johnson asked whether the opioid epidemic would have happened if LSD has been available as a treatment for opioid addiction.
We may be making a mistake making kratom plant alkaloid 7-OH a Schedule 1 drug in 2026 when 23% are using it for opioid abuse recovery.
@dea @hhs @RobertKennedyJr
Matthew W. Johnson retweeted
New piece from me and @Drug_Researcher:
Psychedelics like psilocybin could soon become FDA-approved medicines yet remain Schedule I drugs under federal law.
We explain why rescheduling only patented formulations, rather than the underlying molecules, would be a serious mistake.
Read it now:
tinyurl.com/4uycksyv
Sounding the alarm - if MDMA & psilocybin are approved by FDA, most MDMA & psilocybin could still be scheduled I, wildly inconsistent with the science. @Ravarora1 & I lay out the case for why we need to avoid a "bifurcated schedule" that only reschedules the commercial FDA approved product. Please repost & spread the word! illusionconsensus.com/p/psyc…
Excited to present psychedelic research with @DrDavidRabin at the Beyond Wonderland meeting in Austin. Tickets still available wonderlandconference.com/
My pick for worst drugs would be the volatile anesthetics like ether or, even worse, volitile solvents like gasoline and toluene. Huffing gas is perhaps the most toxic drug use by humans. But notice that we use education and regulation, rather than forbidding the substance, to address the problem.
Just submitted my comments to the federal posting, recommending against this move. Some of the comments already posted are wild. Anonymous posts calling for the abolition of the DEA and Controlled Substances Act, or to schedule alcohol and tobacco, are not a wise strategy. They might make one feel better as an activist, but they might result in the opposite of the intended effect. Respectfully describing the relative lack of public harm associated with these compounds, the modest (but not absent) abuse potential of 2a agonists (including apparent lack of addiction), the medical development and medical potential of this general class of psychedelics, and the barriers to medical development that accompany a Schedule 1 placement, are wiser approaches if you want to have an impact.
BREAKING: DEA Moves Again to Place 5 Tryptamine Psychedelics in Schedule I
Tomorrow, the U.S. Drug Enforcement Administration (DEA) will publish a notice of proposed rulemaking that would place five tryptamines in Schedule I of the Controlled Substances Act. Those five substances are 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT.
Please consider participating in the Psychedelic Community Survey by Daniel Kruger and team! sunybuffalo.qualtrics.com/jf…
Please check out this event next Tuesday In London 7pm when we'll explore psychedelic treatment of tobacco addiction! lnkd.in/e79KQEyW Hosted by the Psychedelic Society.
Matthew W. Johnson retweeted
「日本語版神秘体験質問票（MEQ-4）と挑戦的体験質問票（CEQ-7） 短縮版」を開発（翻訳）しました。
サイケデリック体験における神秘体験や挑戦的体験（バッド・トリップ）を迅速に評価するための尺度です。国内外の先生方と研究協力者の皆様に感謝申し上げます。@Drug_Researcher @juststrickland
New Technical note: Development of Japanese Versions of the 4-Item Mystical Experience Questionnaire and 7-Item Challenging Experience Questionnaire onlinelibrary.wiley.com/doi/…
